Vesper Biotechnologies Logo

Vesper Biotechnologies

Confirm changes

Please review and confirm your changes below.
Please validate captcha

Are you an employee of this fund ?

Add your professional email address below for verification

This email address seems invalid, please retry.

Overview

Who we areWe bring together world class scientists to create revolutionary technology platforms in human health and agriculture.
Vesper Biotechnologies originally started as a traditional venture capital fund. Over time, we pivoted to a biotechnology holding company, focusing on building and scaling startups from the ground up.
Value addWe are a biotech holding company that offers a collaborative portfolio environment, fostering synergy among our companies. With years of experience in management and operations, we provide founders with strategic guidance, access to an extensive network of industry contacts, and the resources needed to accelerate growth. Our hands-on approach ensures tailored support to help navigate the unique challenges of the biotech sector.
We primarily invest in early-stage ventures, often joining as co-founders and actively participating in the company's development. Our approach is highly customized—we work closely with scientists and entrepreneurs to structure investments based on the specific needs and potential of each startup.
Today, our portfolio includes eight companies across agriculture and human health. Headquartered in Florianópolis, Santa Catarina, Brazil, we bring expertise in company management, covering financial strategy, regulatory pathways, and fundraising support.
Firm typeOther
Global HQ

Florianópolis, Santa Catarina, Brazil

Branch office #1
Branch office #2
Branch office #3
Branch office #4
Branch office #5

Thesis

Funding requirementsWe invest in transformative and truly disruptive biotechnology projects, by providing access to capital, our national and international network and, above all, through hard work and a dedicated management team. We stand out for our hands-on, participatory and collaborative management style.
Funding stages1. Idea or Patent2. Prototype3. Early Revenue4. Scaling
LeadN/A
Check sizeN/A
Target countries Brazil

Portfolio

Settings

How to get in touch Email address
Default email or URL to receive deal flow
CRM
Linkedinhttps://www.linkedin.com/company/vesperbiotechnologies/
Twitter
Websitehttps://www.vesper-bio.com/
Loading...
Loading, please wait...

Are you sure you want to contact this investor ?

Pick the best recipient for your submission

Default Email The fund's default email for cold outreach

Send your email

You need to be logged in as a founder to submit your deck to investors.
Sign up or log in now

Please avoid terms like "pitch", "deck", "intro" or "opportunity" in the email subject.

Please remove quotation marks from the start and/or the end of the email subject.

Please don't use full CAPS in the email subject.

Please do not insert an email address in the email subject.

Please do not use "!!" or "??" in the email subject.

- OR -

Start your email with a personal greeting eg. "Hi John," or "Hello XXX Team,".

Please don't include URLs in your email body to maximize reply rate. We already link to your pitch deck and calendar automatically.

Make sure to include numbers (growth, revenue, etc.) in your email to capture attention.

Write shorter paragraphs to improve readibility. You can also use bulletpoints if you need to list down information.

No need to mention OpenVC in your email. Focus the conversation on your business.

Your pitch deck

Choose your pitch deck below:

You need to sign up to upload your deck to OpenVC.
Create an account, it's 100% free !

Please provide a direct link to the pitch deck - not to a folder

Don't share a read-only Google Slides, it may be poorly perceived by some investors. Instead, host a PDF on DocSend or Google Drive and share that link.

Your link doesn't work. We recommend hosting your pitch deck as a PDF on Google Drive, Dropbox, DocSend, etc.

You need to be logged in as a founder to submit your deck to investors.
Sign up or log in now